SHI Link provides business development and transactional services to get your deals done.
Our extensive experience in commercial strategy enables us to find and pick the top priority
programs for your company or position your product attractively for
out-licensing.
out-licensing.
We activate our extensive business development network and transactional leadership - that has
already executed $850 million in upfront and milestone payments in the last decade - to assist you
in accessing products or partners.
Link Events
Client News
NRC-BRI Licenses Clusterin-Specific Antibodies to Alethia Biotherapeutics
Montreal, QC, October 3, 2007 - Alethia Biotherapeutics Inc., a privately held biotechnology company, announced today that it has concluded an agreement on the terms and conditions of an option to license the exclusive worldwide therapeutic and diagnostic rights on clusterin-specific antibodies from the National Research Council Biotechnology Research Institute (NRC-BRI).
Montreal, QC, October 3, 2007 - Alethia Biotherapeutics Inc., a privately held biotechnology company, announced today that it has concluded an agreement on the terms and conditions of an option to license the exclusive worldwide therapeutic and diagnostic rights on clusterin-specific antibodies from the National Research Council Biotechnology Research Institute (NRC-BRI).
